A subset of HIV-positive patients develops salivary gland disease (HIV-SGD), characterized by salivary gland enlargement and/or decreased salivary flow. While clinical symptoms are similar to Sjögren's syndrome (SS), patients with HIV-SGD lack circulating anti-SS-A/Ro and anti-SS-B/La. Occasionally, SS patients lacking circulating anti-SS-A/Ro and anti-SS-B/La have these antibodies in their saliva. Salivas from 11 patients with HIV-SGD, 13 HIV+ patients without HIV-SGD, 14 HIV-negative men controls, and 11 patients with SS were screened for autoantibodies. Five HIV-SGD salivas had antibodies recognizing the cytoplasm of a salivary cell line. No HIV+ controls showed reactivity. Ten of 11 SS patients had salivary autoantibodies, and one HIV-negative control was positive for them. Salivary anti-SS-A/Ro was present in 8/11 SS patients, and 7 also contained anti-SS-B/La. No HIV-SGD salivary samples had these specific autoantibodies. These findings suggest that while glandular polyclonal expansion occurs in both HIV-SGD and SS, different autoantibodies are produced.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0714.1993.tb01057.xDOI Listing

Publication Analysis

Top Keywords

salivary gland
12
patients hiv-sgd
12
salivary
9
salivary autoantibodies
8
gland disease
8
patients
8
circulating anti-ss-a/ro
8
anti-ss-a/ro anti-ss-b/la
8
hiv-sgd
7
autoantibodies hiv-associated
4

Similar Publications

Objective: Salivary gland cancers (SGC) are rare cancers with currently no standard treatment for recurrent/metastatic disease. Based on checkpoint inhibitors benefit in a broad range of tumours, NIvolumab in Salivary gland CArcinoma of the Head and Neck (NISCAHN) evaluated nivolumab efficacy in SGC.

Methods And Analysis: In this phase II single-stage Fleming design, patients with SGC with a progressive disease progression within 6 months prior to entering the study, were divided into ACC (adenoid cytic carcinoma) and non-ACC.

View Article and Find Full Text PDF

Pleomorphic adenoma (PA) is the most common salivary gland tumour. Pre-operative fine-needle aspiration (FNA) is currently one of the most widely used cytological examination techniques for the diagnosis of salivary gland tumours. Because PA exhibits characteristic cytological features, cytological diagnosis is straightforward in most cases.

View Article and Find Full Text PDF

Surgical management of benign tumors of the parotid gland: the advantages of extracapsular dissection compared to traditional surgical techniques.

Front Surg

January 2025

General Surgery III, Department of General Surgery and Medical-Surgical Specialties, University of Catania, AOU Policlinico "G. Rodolico - San Marco", Catania, Italy.

Introduction: Salivary gland tumors represent only 3%-6% of all head and neck neoplasms, and approximately 70% of these tumors are located in the parotid gland. Most of these tumors are found in the more abundant superficial portion of the parotid gland, lateral to the facial nerve (FN). For many years, the location of the facial nerve between the superficial and deep segments of the parotid gland hindered adequate tumor extirpation.

View Article and Find Full Text PDF

Surgical non-aggressive approach for the delivery of 4 cm salivary stone from the submandibular gland duct: Avoiding salivary gland removal - A case report.

Int J Surg Case Rep

January 2025

Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Tishreen University Hospital, Tishreen University, Latakia, Syria. Electronic address:

Introduction And Importance: Salivary calculi represent the most common salivary gland disease. It can vary significantly in size, ranging from less than 1 mm to several centimeters. As the size of the stone increases, the surgical approach becomes more complex and the function of the gland may be compromised, potentially necessitating total gland removal.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!